Allergy Therapeutics Plc (AGY) – Strategy, SWOT and Corporate Finance Report

Allergy Therapeutics Plc (AGY) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Allergy Therapeutics Plc (Allergy Therapeutics) is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers aluminum-free allergy vaccines and diagnostics. Allergy Therapeutics product portfolio includes Grass Modified Allergen Tyrosine Adsorbed (MATA), Tree MATA, Ragweed MATA, Bee Venom Subcutaneous Immunotherapy (SCIT), and Wasp venom SCIT among others. It also offers allergen extracts used for skin prick testing. The company’s diagnostics products comprise Pollen, Moulds, Arthropods, Epithelia and others. It has an operational presence in Germany, Italy, Spain, Austria, Switzerland, the Netherlands and the UK, among others. Allergy Therapeutics is headquartered in Worthing, West Sussex, the UK.

Scope

• Detailed information on Allergy Therapeutics Plc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Allergy Therapeutics Plc in the form of a SWOT analysis

• An in-depth view of the business model of Allergy Therapeutics Plc including a breakdown and examination of key business segments

• News about Allergy Therapeutics Plc, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Allergy Therapeutics Plc and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Allergy Therapeutics Plc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Allergy Therapeutics Plcs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

HAL Allergy BV

Stallergenes Greer Ltd

Roxall Medizin GmbH

Laboratorios LETI SLU

Biomay AG

Allergopharma GmbH & Co KG

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Allergy Therapeutics Plc - Key Facts

Allergy Therapeutics Plc - Key Employees

Allergy Therapeutics Plc - Key Employee Biographies

Allergy Therapeutics Plc - Major Products and Services

Allergy Therapeutics Plc - History

Allergy Therapeutics Plc - Company Statement

Allergy Therapeutics Plc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Allergy Therapeutics Plc - Business Description

Geographical Segment: Central Europe

Target Markets

Performance

Geographical Segment: Rest of World (including UK)

Performance

Geographical Segment: Southern Europe

Target Markets

Performance

R&D Overview

Allergy Therapeutics Plc - Corporate Strategy

Allergy Therapeutics Plc - SWOT Analysis

SWOT Analysis - Overview

Allergy Therapeutics Plc - Strengths

Allergy Therapeutics Plc - Weaknesses

Allergy Therapeutics Plc - Opportunities

Allergy Therapeutics Plc - Threats

Allergy Therapeutics Plc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Allergy Therapeutics Plc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Sep 27, 2023: Allergy Therapeutics : Unaudited Preliminary Results for the Year Ended 30 June 2023

Aug 10, 2023: Allergy Therapeutics : Trading update for the year ended 30 June 2023

Apr 06, 2023: Allergy Therapeutics : Trading and business update and update on annual report and accounts

Jan 20, 2023: Allergy Therapeutics : Half-year trading update 2023

Jan 13, 2023: Allergy Therapeutics Announces Notice of 2022 Annual General Meeting

Dec 29, 2022: Allergy Therapeutics PLC Annual Report and Accounts Delayed

Dec 28, 2022: Allergy Therapeutics Announces Scott Leinenweber Resign as Non-Executive Director

Dec 06, 2022: Allergy Therapeutics : Appointment of Non-Executive Directors

Oct 28, 2022: Allergy to resume UK manufacturing production

Sep 28, 2022: Allergy Therapeutics : Unaudited preliminary results for the Year ended 30 June 2022

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Allergy Therapeutics Plc, Key Facts

Allergy Therapeutics Plc, Key Employees

Allergy Therapeutics Plc, Key Employee Biographies

Allergy Therapeutics Plc, Major Products and Services

Allergy Therapeutics Plc, History

Allergy Therapeutics Plc, Subsidiaries

Allergy Therapeutics Plc, Key Competitors

Allergy Therapeutics Plc, Annual Ratios

Allergy Therapeutics Plc, Annual Ratios (Cont…1)

Allergy Therapeutics Plc, Annual Ratios (Cont…2)

Allergy Therapeutics Plc, Interim Ratios

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Allergy Therapeutics Plc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Allergy Therapeutics Plc, Performance Chart (2019 – 2023)

Allergy Therapeutics Plc, Ratio Charts

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Allergy Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports